{
    "clinical_study": {
        "@rank": "83912", 
        "arm_group": [
            {
                "arm_group_label": "EPI-743 15 mg/kg", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects in this arm will receive EPI-743 at a dose of 15 mg/kg three times daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects in this arm will receive placebo at a volume equivalent to the volume of EPI-743 they would receive if in active group based on their weight"
            }
        ], 
        "brief_summary": {
            "textblock": "Rett syndrome is a severe neurodevelopmental disorder that primarily affects female\n      children. Rett syndrome is characterized by significant elevation in blood markers of\n      oxidative stress. EPI-743 is a novel therapeutic with demonstrated efficacy and safety in\n      the treatment of disorders characterized by oxidative stress. The purpose of this study is\n      to examine the safety and efficacy of EPI-743 in a population of children with Rett\n      syndrome."
        }, 
        "brief_title": "Phase 2 Study of EPI-743 for Treatment of Rett Syndrome", 
        "condition": "Rett Syndrome", 
        "condition_browse": {
            "mesh_term": "Rett Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of Rett syndrome with disease stage 1-2\n\n          -  Abnormality of at least two disease biomarker levels\n\n          -  Confirmed MeCP2 mutation\n\n          -  Patient or patient's guardian able to consent and comply with protocol requirements\n\n          -  Abstention from use of Coenzyme Q10, vitamin E and Idebenone two weeks prior to\n             enrollment into the study\n\n        Exclusion Criteria:\n\n          -  Any condition, which in the opinion of the investigator could compromise the\n             subject's safety or adherence to treatment with EPI-743.\n\n          -  Clinically significant allergy or hypersensitivity to EPI-743 or to any of the\n             excipients of with EPI-743 (eg., sesame oil).\n\n          -  Clinically significant allergy or hypersensitivity to Vitamin E\n\n          -  Lack of confirmation of MeCP2 mutation\n\n          -  Clinical history of bleeding or abnormal baseline PT/PTT\n\n          -  Diagnosis of any other concurrent inborn error of metabolism\n\n          -  Hepatic insufficiency with LFTs greater than 3 times upper limit of normal\n\n          -  Renal insufficiency requiring dialysis\n\n          -  End stage cardiac failure\n\n          -  Fat malabsorption syndromes precluding drug absorption"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01822249", 
            "org_study_id": "OPBGC&RS_12_003"
        }, 
        "intervention": {
            "arm_group_label": "EPI-743 15 mg/kg", 
            "intervention_name": "EPI-743", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rett syndrome", 
            "EPI-743", 
            "Edison"
        ], 
        "lastchanged_date": "May 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Siena", 
                    "country": "Italy"
                }, 
                "name": "University of Siena"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children With Rett Syndrome", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measure of disease progression", 
            "measure": "Rett Syndrome Clinical Severity Sore", 
            "safety_issue": "No", 
            "time_frame": "Change at six months from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01822249"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Oxidative Stress Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Change at six months from baseline"
            }, 
            {
                "measure": "Head circumference", 
                "safety_issue": "No", 
                "time_frame": "Change at six months from baseline"
            }, 
            {
                "measure": "Rett syndrome behavioral questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Change at six months from baseline"
            }, 
            {
                "measure": "PedsQL", 
                "safety_issue": "No", 
                "time_frame": "Change at six months from baseline"
            }, 
            {
                "measure": "Number of Drug-related adverse and serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Six months"
            }, 
            {
                "description": "RDI will be determined on polysomnography study", 
                "measure": "Respiratory Disturbance Index (RDI)", 
                "safety_issue": "No", 
                "time_frame": "Change at six months from baseline"
            }
        ], 
        "source": "Edison Pharmaceuticals Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Edison Pharmaceuticals Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}